FdaApplication
BLA 125740
Identifiers
- fda_app_no: BLA125740
Properties
| Property | Value |
|---|---|
| applicant_name | Pfizer Ireland Pharmaceuticals Unlimited Company |
| application_type | BLA |
| approval_date | 2021-08-13 |
Revenue by product
TICOVAC
| Period | Revenue |
|---|---|
| Q2 2026 | $132.0M |
| Q1 2026 | $81.0M |
| Q3 2025 | $100.0M |
| Q2 2025 | $109.0M |
| Q1 2025 | $63.0M |
| Q3 2024 | $81.0M |
| Q2 2024 | $100.0M |
| Q4 2023 | $31.0M |
| Q3 2023 | $91.0M |
| Q2 2023 | $101.0M |
| Q1 2023 | $45.0M |
| Q4 2022 | $23.0M |
| Q3 2022 | $67.0M |
| Q2 2022 | $68.0M |
| Q1 2022 | $42.0M |
| Q4 2021 | $24.0M |
| Q3 2021 | $47.0M |
| Q2 2021 | $61.0M |
| Q1 2021 | $53.0M |
| Q4 2020 | $26.0M |
| Q3 2020 | $77.0M |
| Q2 2020 | $45.0M |
| Q1 2020 | $48.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TICOVAC | — | 1.2UG/0.25ML | Injection |
| TICOVAC | — | 2.4UG/0.5ML | Injection |
2 products